Comparing the toxicity effects of copper oxide nanoparticles conjugated with Lapatinib on breast (MDA-MB-231) and lung (A549) cancer cell lines
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-03071-1 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Masoumeh Valizadeh Talarposhti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran. Hauptthemen laut MEDLINE: Lapatinib, Copper, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran.
- Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran. salehzadeh@iaurasht.ac.ir.
- Department of Biology, Faculty of Science, Arak University, Arak, 384817758, Iran.
Zitieren
APA
Talarposhti, M. V., Salehzadeh, A., & Jalali, A. (2024). Comparing the toxicity effects of copper oxide nanoparticles conjugated with Lapatinib on breast (MDA-MB-231) and lung (A549) cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03071-1
Vancouver
Talarposhti MV, Salehzadeh A, Jalali A. Comparing the toxicity effects of copper oxide nanoparticles conjugated with Lapatinib on breast (MDA-MB-231) and lung (A549) cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03071-1
BibTeX
@article{Talarposhti2024,
author = {Talarposhti, Masoumeh Valizadeh and Salehzadeh, Ali and Jalali, Amir},
title = {Comparing the toxicity effects of copper oxide nanoparticles conjugated with Lapatinib on breast (MDA-MB-231) and lung (A549) cancer cell lines},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-03071-1}
}
EUVIMED